Chemoprevention in patients with genetic risk of colorectal cancers

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res.36(7 Pt 2),2699–2702 (1976).
  Medline CASGoogle Scholar
• 2  Sporn MB. Combination chemoprevention of cancer. Nature287(5778),107–108 (1980).
  Medline CASGoogle Scholar
• 3  Levin B. Genetic syndromes as potential targets for chemoprevention of colorectal neoplasia. J. Cell Biochem. Suppl.34,19–22 (2000).
  Medline CASGoogle Scholar
• 4  Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med.355(9),873–884 (2006).
  Medline CASGoogle Scholar
• 5  Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med.355(9),885–895 (2006).
  Medline CASGoogle Scholar
• 6  Baron JA, Sandler RS, Bresalier RS et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology131(6),1674–1682 (2006).
  Medline CASGoogle Scholar
• 7  Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med.355(9),950–952 (2006).
  Medline CASGoogle Scholar
• 8  Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med.348(10),891–899 (2003).
  Medline CASGoogle Scholar
• 9  Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med.348(10),883–890 (2003).
  Medline CASGoogle Scholar
• 10  Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet369(9573),1603–1613 (2007).
  Medline CASGoogle Scholar
• 11  Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br. J. Cancer105(8),1107–1113 (2011).
  Medline CASGoogle Scholar
• 12  Lippman SM, Lee JJ. Reducing the “risk” of chemoprevention: defining and targeting high risk – 2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res.66(6),2893–2903 (2006).
  Medline CASGoogle Scholar
• 13  Sporn MB, Hong WK. Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nat. Clin. Pract. Oncol.5(11),628–629 (2008).
  Medline CASGoogle Scholar
• 14  Sporn MB, Hong WK. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prev. Res. (Phila.)1(1),9–11 (2008).▪ Seminal paper describing the concept of combinations of pharmaceutical agents for cancer prevention; outlined the rationale for this approach, including the reduction of agent toxicities and the ability to target multiple features of cancer development.
  Medline CASGoogle Scholar
• 15  Bulow S, Faurschou Nielsen T, Bulow C, Bisgaard Ml, Karlsen L, Moesgaard F. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int. J. Colorectal Dis.11(2),88–91 (1996).
  Medline CASGoogle Scholar
• 16  Burn J, Chapman P, Delhanty J et al. The UK northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J. Med. Genet.28(5),289–296 (1991).
  Medline CASGoogle Scholar
• 17  Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut33(3),357–360 (1992).
  Medline CASGoogle Scholar
• 18  Bulow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis. Colon Rectum29(2),102–107 (1986).
  Medline CASGoogle Scholar
• 19  Newton K, Mallinson E, Bowen J et al. Genotype–phenotype correlation in colorectal polyposis. Clin. Genet.81(6),521–531 (2011).
  MedlineGoogle Scholar
• 20  Banasiewicz T, Marciniak R, Kaczmarek E et al. The prognosis of clinical course and the analysis of the frequency of the inflammation and dysplasia in the intestinal J-pouch at the patients after restorative proctocolectomy due to FAP. Int. J. Colorectal Dis.26(9),1197–1203 (2011).
  MedlineGoogle Scholar
• 21  Erkek AB, Church JM, Remzi FH. Age-related analysis of functional outcome and quality of life after restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. J. Gastroenterol. Hepatol.22(5),710–714 (2007).
  MedlineGoogle Scholar
• 22  Bulow S. Results of national registration of familial adenomatous polyposis. Gut52(5),742–746 (2003).
  Medline CASGoogle Scholar
• 23  Chew MH, Quah HM, Teh KL, Loi TT, Eu KW, Tang CL. Twenty years of familial adenomatosis polyposis syndromes in the Singapore Polyposis Registry: an analysis of outcomes. Singapore Med. J.52(4),246–251 (2011).
  Medline CASGoogle Scholar
• 24  De Zeeuw S, Heikens JT, Gooszen HG, Van Laarhoven CJ. The ileo neo-rectal anastomosis in patients with familial adenomatous polyposis: a prospective case series with long-term follow-up. Colorectal Dis. doi:10.1111/j.1463-1318.2011.02806.x. (2011) (Epub ahead of print).
  Google Scholar
• 25  Fritzell K, Eriksson LE, Bjork J, Hultcrantz R, Wettergren L. Self-reported abdominal symptoms in relation to health status in adult patients with familial adenomatous polyposis. Dis. Colon Rectum54(7),863–869 (2011).
  MedlineGoogle Scholar
• 26  McNicol F, Kennedy R, Phillips R, Clark S. Laparoscopic total colectomy and ileorectal anastomosis (IRA), supported by an enhanced recovery programme in cases of familial adenomatous polyposis. Colorectal Dis.14(4),458–462 (2012).
  Medline CASGoogle Scholar
• 27  Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int. J. Colorectal Dis.26(11),1365–1374 (2011).
  MedlineGoogle Scholar
• 28  Nieuwenhuis MH, Douma KF, Bleiker EM, Bemelman WA, Aaronson NK, Vasen HF. Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study. Ann Surg252(2),341–344 (2010).
  MedlineGoogle Scholar
• 29  Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg. Clin. North Am.88(4),819–844, vii (2008).
  MedlineGoogle Scholar
• 30  Anderson BJ, Wolpert HA. A developmental perspective on the challenges of diabetes education and care during the young adult period. Patient Educ. Couns.53(3),347–352 (2004).
  MedlineGoogle Scholar
• 31  Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther.2(4 Suppl. 1),S140–S149 (2003).▪ Summary of benefits of NSAIDs in familial adenomatous polyposis, especially sulindac.
  Medline CASGoogle Scholar
• 32  Burn J, Bishop DT, Chapman PD et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev. Res. (Phila.)4(5),655–665 (2011).
  Medline CASGoogle Scholar
• 33  Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer. an analysis from the CAPP2 randomised controlled trial. Lancet378(9809),2081–2087 (2012).▪ Showed benefit of aspirin in patients with hereditary nonpolyposis colorectal cancer; and underscored the problem of using cancer and death as end points.
  Google Scholar
• 34  Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med.328(18),1313–1316 (1993).
  Medline CASGoogle Scholar
• 35  Giardiello FM, Yang VW, Hylind LM et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med.346(14),1054–1059 (2002).
  Medline CASGoogle Scholar
• 36  Labayle D, Fischer D, Vielh P et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology101(3),635–639 (1991).
  Medline CASGoogle Scholar
• 37  Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg.80(12),1618–1619 (1993).
  Medline CASGoogle Scholar
• 38  Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract. Res. Clin. Gastroenterol.25(4–5),607–622 (2011).▪ Reviews all previous trials of familial adenomatous polyposis chemoprevention.
  Medline CASGoogle Scholar
• 39  De Leng WW, Westerman AM, Weterman MA et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin. Cancer Res.9(8),3065–3072 (2003).
  Medline CASGoogle Scholar
• 40  Akasu T, Yokoyama T, Sugihara K, Fujita S, Moriya Y, Kakizoe T. Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study. Hepatogastroenterology49(47),1259–1261 (2002).
  MedlineGoogle Scholar
• 41  Hirota C, Iida M, Aoyagi K et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer78(8),1660–1665 (1996).
  Medline CASGoogle Scholar
• 42  Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut55(3),367–373 (2006).
  Medline CASGoogle Scholar
• 43  Van Stolk R, Stoner G, Hayton Wl et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res.6(1),78–89 (2000).
  Medline CASGoogle Scholar
• 44  Stoner GD, Budd GT, Ganapathi R et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exp. Med. Biol.470,45–53 (1999).
  Medline CASGoogle Scholar
• 45  Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med.342(26),1946–1952 (2000).
  Medline CASGoogle Scholar
• 46  Hallak A, Alon-Baron L, Shamir R et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig. Dis. Sci.48(10),1998–2002 (2003).
  Medline CASGoogle Scholar
• 47  Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer Res.9(13),4756–4760 (2003).
  Medline CASGoogle Scholar
• 48  Iwama T, Akasu T, Utsunomiya J, Muto T. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int. J. Clin. Oncol.11(2),133–139 (2006).
  Medline CASGoogle Scholar
• 49  Bertagnolli MM, Eagle CJ, Zauber AG et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. (Phila.)2(4),310–321 (2009).
  Medline CASGoogle Scholar
• 50  Solomon SD, Mcmurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352(11),1071–1080 (2005).
  Medline CASGoogle Scholar
• 51  Solomon SD, Pfeffer MA, Mcmurray JJ et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation114(10),1028–1035 (2006).
  Medline CASGoogle Scholar
• 52  Solomon SD, Wittes J, Finn PV et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. The cross trial safety analysis. Circulation117(16),2104–2113 (2008).
  Medline CASGoogle Scholar
• 53  He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science281(5382),1509–1512 (1998).
  Medline CASGoogle Scholar
• 54  Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer4(10),781–792 (2004).
  Medline CASGoogle Scholar
• 55  Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr. Cancer60(Suppl. 1),30–35 (2008).
  MedlineGoogle Scholar
• 56  Meyskens FL Jr, Mclaren CE, Pelot D et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila.)1(1),32–38 (2008).
  Medline CASGoogle Scholar
• 57  Lynch PM. Eicosapentaenoic acid and chemoprevention of FAP. Gut59(7),871–873 (2010).
  Medline CASGoogle Scholar
• 58  West NJ, Clark SK, Phillips RK et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut59(7),918–925 (2010).
  Medline CASGoogle Scholar
• 59  Decosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J. Natl Cancer Inst.81(17),1290–1297 (1989).
  Medline CASGoogle Scholar
• 60  Thomas MG, Thomson JP, Williamson RC. Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis. Br. J. Surg.80(4),499–501 (1993).
  Medline CASGoogle Scholar
• 61  Cruz-Correa M, Shoskes DA, Sanchez P et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin. Gastroenterol. Hepatol.4(8),1035–1038 (2006).
  Medline CASGoogle Scholar
• 62  Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (IGC-HNPCC). Dis. Colon Rectum34,424–425 (1991).
  Medline CASGoogle Scholar
• 63  Vasen HFA, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology116,1453–1456 (1999).
  Medline CASGoogle Scholar
• 64  Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst.89,1758–1762 (1997).
  Medline CASGoogle Scholar
• 65  Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21),2042–2054 (2003).
  Medline CASGoogle Scholar
• 66  Dunlop MG, Farrington SM, Nicholl I et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br. J. Cancer83(12),1643–1645 (2000).
  Medline CASGoogle Scholar
• 67  Parry S, Win AK, Parry B et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers. The advantage of more extensive colon surgery. Gut60(7),950–957 (2011).
  MedlineGoogle Scholar
• 68  Kalady MF. Surgical management of hereditary nonpolyposis colorectal cancer. Adv. Surg.45,265–274 (2011).
  MedlineGoogle Scholar
• 69  Vasen HF, Abdirahman M, Brohet R et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology138(7),2300–2306 (2010).
  MedlineGoogle Scholar
• 70  Sinicrope FA, Lemoine M, Xi L et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology117(2),350–358 (1999).
  Medline CASGoogle Scholar
• 71  Castells A, Paya A, Alenda C et al. Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin. Cancer Res.12(6),1686–1692 (2006).
  Medline CASGoogle Scholar
• 72  Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer1(1),11–21 (2001).
  Medline CASGoogle Scholar
• 73  Poley JW, Wagner A, Hoogmans MM et al. Biallelic germline mutations of mismatch-repair genes. a possible cause for multiple pediatric malignancies. Cancer109(11),2349–2356 (2007).
  MedlineGoogle Scholar
• 74  Herkert JC, Niessen RC, Olderode-Berends MJ et al. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations. case series, review and follow-up guidelines. Eur. J. Cancer47(7),965–982 (2011).
  Medline CASGoogle Scholar
• 75  Kucherlapati MH, Lee K, Nguyen AA et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology138(3),993–1002.e1 (2010).
  MedlineGoogle Scholar
• 76  Mcilhatton MA, Tyler J, Kerepesi LA et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev. Res. (Phila.)4(5),684–693 (2011).
  Medline CASGoogle Scholar
• 77  Mcilhatton MA, Tyler J, Burkholder S et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res.67(22),10966–10975 (2007).
  Medline CASGoogle Scholar
• 78  Itano O, Yang K, Fan K et al. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis30(11),1923–1926 (2009).
  Medline CASGoogle Scholar
• 79  Lal G, Ash C, Hay K et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res.61(16),6131–6136 (2001).
  Medline CASGoogle Scholar
• 80  Mladenova D, Daniel JJ, Dahlstrom JE et al. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut60(3),350–360 (2011).
  Medline CASGoogle Scholar
• 81  Burn J, Bishop DT, Mecklin JP et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med.359(24),2567–2578 (2008).
  Medline CASGoogle Scholar
• 82  Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med.333(10),609–614 (1995).
  Medline CASGoogle Scholar
• 83  Liljegren A, Barker G, Elliott F et al. Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants. report by the colorectal adenoma/carcinoma prevention programme 2. J. Clin. Oncol.26(20),3434–3439 (2008).
  MedlineGoogle Scholar
• 84  Rijcken FE, Hollema H, Van Der Zee AG, Van Der Sluis T, Boersma-Van EK W, Kleibeuker JH. Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur. J. Cancer43(8),1251–1256 (2007).
  Medline CASGoogle Scholar
• 85  Tsilidis KK, Allen NE, Key TJ et al. Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Br. J. Cancer103(11),1755–1759 (2010).
  Medline CASGoogle Scholar
• 86  Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G.C-->T:A mutations in colorectal tumors. Nat. Genet.30(2),227–232 (2002).
  Medline CASGoogle Scholar
• 87  Vogt S, Jones N, Christian D et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology137(6),1976–1985 e1971–1910 (2009).
  Medline CASGoogle Scholar
• 88  Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science280(5366),1036–1037 (1998).
  Medline CASGoogle Scholar
• 89  Martinez ME, O’Brien TG, Fultz KE et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl Acad. Sci. USA100(13),7859–7864 (2003).
  Medline CASGoogle Scholar
• 90  Zell JA, Mclaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J. Natl Cancer Inst.102(19),1513–1516 (2010).
  Medline CASGoogle Scholar
• 91  Thompson PA, Wertheim BC, Zell JA et al. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology139(3),797–805.e1 (2010).
  Medline CASGoogle Scholar
• 92  MHRA. Onsenal (Celecoxib) for familial adenomatous polyposis: withdrawal from EU market. MHRA Drug Safety Update1(5),CON125965 (2011).
  Google Scholar
• 93  Brosens LA, Langeveld D, Van Hattem WA, Giardiello FM, Offerhaus GJ. Juvenile polyposis syndrome. World J. Gastroenterol.17(44),4839–4844 (2011).
  Medline CASGoogle Scholar
• 94  Kurland JE, Beck SE, Solomon CJ, Brann OS, Carethers JM, Huang SC. Cyclooxygenase-2 expression in polyps from a patient with juvenile polyposis syndrome with mutant BMPR1A. J. Pediatr. Gastroenterol. Nutr.44(3),318–325 (2007).
  Medline CASGoogle Scholar
• 95  Kuwada SK, Burt R. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome. Fam. Cancer10(3),469–472 (2011).
  Medline CASGoogle Scholar
• 96  Udd L, Katajisto P, Rossi DJ et al. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology127(4),1030–1037 (2004).
  Medline CASGoogle Scholar
• 97  Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology139(6),1927–1933 (2010).
  Medline CASGoogle Scholar
• 98  Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer11(4),289–301 (2011).
  Medline CASGoogle Scholar
• 99  Lopiccolo J, Ballas MS, Dennis PA. PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit. Rev. Oncol. Hematol.63(3),203–214 (2007).
  MedlineGoogle Scholar
• 100  Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res.18(2),400–407 (2012).
  Medline CASGoogle Scholar
• 101  Aspirin and Eflornithine in Treating Patients at High Risk for Colorectal Cancer. http://clinicaltrials.gov/ct2/show/NCT00983580
  Google Scholar
• 102  Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis. http://clinicaltrials.gov/ct2/show/NCT00319007?term=NCT00319007&rank=1
  Google Scholar
• 103  Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis. http://clinicaltrials.gov/ct2/show/NCT00026468?term=exisulind+FAP&rank=1
  Google Scholar
• 104  Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP). http://clinicaltrials.gov/ct2/show/NCT01483144
  Google Scholar
• 105  Chemoprevention Trial in Familial Adenomatous Polyposis Coli Using EPA. http://clinicaltrials.gov/ct2/show/NCT00510692?term=NCT00510692&rank=1
  Google Scholar
• 106  Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP). http://clinicaltrials.gov/ct2/show/NCT00770991?term=NCT00770991&rank=1
  Google Scholar
• 107  Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients. http://clinicaltrials.gov/ct2/show/NCT00151476?term=NCT00151476&rank=1
  Google Scholar
• 108  A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP). http://clinicaltrials.gov/ct2/show/NCT00140894?term=NCT00140894&rank=1
  Google Scholar
• 109  Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients. http://clinicaltrials.gov/ct2/show/NCT00248053?term=NCT00248053&rank=1
  Google Scholar
• 110  Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis. http://clinicaltrials.gov/ct2/show/NCT00033371?term=NCT00033371&rank=1
  Google Scholar
• 111  Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) (CHIP). http://clinicaltrials.gov/ct2/show/NCT00585312?term=NCT00585312&rank=1
  Google Scholar
• 112  Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP). http://clinicaltrials.gov/ct2/show/NCT00641147?term=NCT00641147&rank=1
  Google Scholar
• 113  Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP). http://clinicaltrials.gov/ct2/show/NCT00927485?term=NCT00927485&rank=1
  Google Scholar
• 114  A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients. http://clinicaltrials.gov/ct2/show/NCT01187901?term=NCT01187901&rank=1
  Google Scholar
• 115  A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome. http://clinicaltrials.gov/ct2/show/NCT01286662?term=NCT01286662&rank=1
  Google Scholar
• 116  Coxib-inhibition of Duodenal Polyp Growth in FAP. http://clinicaltrials.gov/ct2/show/NCT00844727?term=NCT00844727&rank=1
  Google Scholar
• 117  Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis (PreDuoFAP). http://clinicaltrials.gov/ct2/show/NCT00808743?term=NCT00808743&rank=1
  Google Scholar
• 118  Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients. http://clinicaltrials.gov/ct2/show/NCT00134758?term=NCT00134758&rank=1
  Google Scholar
• 119  A Randomised Controlled Trial of Colorectal Polyp and Cancer Prevention Using Aspirin and Resistant Starch in Carriers of Hereditary Nonpolyposis Colorectal Cancer. www.controlled-trials.com/ISRCTN59521990
  Google Scholar
• 120  Phase I–II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase-2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers. http://clinicaltrials.gov/ct2/show/NCT00001693
  Google Scholar
• 121  Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome. http://clinicaltrials.gov/ct2/show/NCT00566644?term=NCT00566644&rank=1
  Google Scholar
• 122  Hormone Therapy in Preventing Endometrial Carcinogenesis (Cancer) in Women With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer. http://clinicaltrials.gov/ct2/show/NCT00033358?term=NCT00033358&rank=1
  Google Scholar